A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

NCT06073860 · clinicaltrials.gov ↗

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Beta Thalassemia

Interventions

DRUG: Luspatercept

Sponsor

Bristol-Myers Squibb